Home World News Cabozantinib Improves PFS in Patients with Previously Treated, Progressive Advanced Extrapancreatic or... World News Cabozantinib Improves PFS in Patients with Previously Treated, Progressive Advanced Extrapancreatic or Pancreatic Neuroendocrine Tumours By Ogkologos - October 25, 2024 979 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CABINET study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma March 16, 2026 Qué debe saber sobre las pruebas de ADN en el hogar... February 8, 2023 FDA Approves Enfortumab Vedotin-ejfv with Pembrolizumab for Locally Advanced or Metastatic... January 8, 2024 Immunotherapy Drug Tebentafusp Improves Survival in Advanced Uveal Melanoma April 29, 2021 Load more HOT NEWS EMA Recommends Extension of Indications for Atezolizumab The (un)usual suspects – how early detection research embraces interdisciplinary science Fosnetupitant Is Valuable in the Prophylaxis of Acute, Delayed, and Beyond... FDA Approves Elacestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast...
